GleamWall
中文EN

CPHI CHINA PHARMA HOLDINGS, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.4%
TTM net income YoY-79.5%
TTM EPS YoY71.8%
Revenue 3-yr CAGR-17.9%
Net income 3-yr CAGR—

Margins

Gross margin14.2%
Operating margin-130.5%
Net margin-132.8%
FCF margin—
EBITDA margin-89.0%

Returns

ROE-24.2%
ROA-18.3%
ROIC (approx.)-20.5%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets16.8%
Debt / equity0.00x
Current ratio0.77x
Interest coverage-157.66x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.14M$4.53M
Cost of revenue$4.28M$6.51M
Gross profit-$131,950-$1.99M
R&D expense$280,901$283,942
SG&A expense$2.45M$1.78M
Operating income-$3.24M-$4.59M
Interest expense$27,272$27,353
Pretax income-$3.19M-$4.74M
Net income-$3.19M-$4.74M
EBITDA-$1.74M-$1.97M
EPS (basic)-0.74-2.71
EPS (diluted)-0.74-2.71
Balance sheet
Cash & equivalents$345,112$626,879
Receivables$241,412$232,140
Inventory$1.62M$2.27M
Current assets$2.35M$3.27M
PP&E, net$4.39M$4.88M
Intangibles$24.08M$6.70M
Total assets$31.00M$14.89M
Current liabilities$7.40M$5.02M
Short-term debt$1.44M$1.14M
Total liabilities$8.26M$7.14M
Shareholders' equity$22.74M$7.75M
Shares outstanding5.52M3.26M
Cash flow statement
Operating cash flow$148,261-$406,063
Capital expenditure$59,324$38,411
Free cash flow$88,937-$444,474
Investing cash flow-$137,251-$291,718
Financing cash flow-$294,027-$33,782
Depreciation & amortization$1.50M$2.62M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.